Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profileAbpro and Celltrion have a strategic partnership for worldwide development and commercialization of ...

T cell activation requires a T cell receptor (TCR) to recognize its cognate peptide in the context of an MHC molecule. In addition, the association of CD3 with the TCR–peptide–MHC complex ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

These optimal TCRs are combined with a CD3 T cell-engaging antibody. The resulting TCR-TCEs direct the patient's T cells ...

CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells.

Overall, patients remained persistently immunosuppressed after infusion, with 48.1% having CD4+ T cell counts of less than 200/µL and median CD3-19+ B cell counts of zero through one-year post-CAR T. ...

When naive T cells encounter antigen-presenting cells (APCs), membrane and cytoplasmic molecules rearrange at the T cell–APC contact area to form the immune synapse. Finetti et al. now reveal an ...

CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on ...

About ProBio's T-Cell Engager and Antibody Discovery Platform CD3 T-cell engagers (TCEs) are a promising strategy in cancer immunotherapy, that are often constrained by safety concerns ...

AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation that includes preclinical in vivo data on its PSMA x CD3 T-cell engagers at the American Association for Cancer Research Ⓡ ...